- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Natco Pharma net profit rises 73 percent to Rs 204 crore in Q2
New Delhi: Drug firm Natco Pharma on Thursday reported a 73.23 percent increase in its consolidated net profit to Rs 203.9 crore for the quarter ended September mainly on account of robust sales.The company had posted a net profit of Rs 117.7 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.Consolidated total income of the company stood at Rs...
New Delhi: Drug firm Natco Pharma on Thursday reported a 73.23 percent increase in its consolidated net profit to Rs 203.9 crore for the quarter ended September mainly on account of robust sales.
The company had posted a net profit of Rs 117.7 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.
Consolidated total income of the company stood at Rs 827.9 crore for the quarter under consideration. It was Rs 518.9 crore for the same period a year ago, it added.
The board of directors has recommended a second interim dividend of Rs 3 per equity share of Rs 2 each for the financial year 2020-21, the filing said.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751